NCT07870668CompletedPhase 4
Intermittent Phentermine for Obesity and Body Composition
Adaptive Pharmacotherapy in Obesity: Intermittent Phentermine Improves Visceral Adiposity and Body Composition
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
This study evaluated the effects of intermittent phentermine treatment on body fat, estimated visceral adiposity, body composition, and tolerability in adults with overweight or obesity. A total of 600 adults aged 21 to 40 years with a body mass index (BMI) between 27 and 35 kg/m² participated in a single-center, randomized, four-group clinical trial conducted at Hospital Médica Campestre in León, Guanajuato, Mexico. Participants were assigned to lifestyle modification alone or lifestyle modification combined with phentermine at doses of 15 mg, 30 mg, or 37.5 mg daily. Phentermine was administered intermittently using a schedule of three months of treatment followed by one month without medication during a 14-month observation period. All participants received nutritional guidance and physical activity recommendations. Body composition was assessed using bioelectrical impedance analysis and three-dimensional body scanning. The primary outcome was the relative percentage reduction in total body fat from baseline to Month 14. Secondary outcomes included estimated visceral adiposity, waist circumference, lean body mass, body weight, BMI, medication adherence, resting heart rate, blood pressure, treatment-emergent adverse events, and treatment discontinuation. The study aimed to evaluate the dose-response effects of intermittent phentermine on body composition and the balance between efficacy and tolerability.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 600 (actual)
- First submitted
- 6 Oct 2026
- Start date
- 1 Mar 2024
- Primary completion date
- 15 Jan 2026
- Lead sponsor
- OSCAR MANUEL TORRES FALCON
- Diseases
- Obesity
- NCT number
- NCT07870668
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 600
- From 1 Mar 2024 to the primary completion date, 15 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known contraindication to sympathomimetic therapy.
Other illness
- Uncontrolled hypertension.
- Clinically significant cardiovascular disease.
- Medical or psychiatric conditions judged to make participation unsafe or compromise protocol adherence.
Other
- Pregnancy or breastfeeding.
Who the study is looking for
- Age 21 to 40 years.
- Body mass index (BMI) 27 to 35 kg/m².
- Eligible for structured obesity treatment.
- Willingness to complete serial body-composition assessments.
Age in the registry: 21 years to 40 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Medica Campestre Coordinator of this site? Confirm its status | León | Mexico | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.